MX2011011217A - Metodo para mejorar el perfil de disolucion de un material biologicamente activo. - Google Patents

Metodo para mejorar el perfil de disolucion de un material biologicamente activo.

Info

Publication number
MX2011011217A
MX2011011217A MX2011011217A MX2011011217A MX2011011217A MX 2011011217 A MX2011011217 A MX 2011011217A MX 2011011217 A MX2011011217 A MX 2011011217A MX 2011011217 A MX2011011217 A MX 2011011217A MX 2011011217 A MX2011011217 A MX 2011011217A
Authority
MX
Mexico
Prior art keywords
active material
biologically active
improving
dissolution profile
milling
Prior art date
Application number
MX2011011217A
Other languages
English (en)
Other versions
MX360545B (es
Inventor
Marck Norret
Aaron Dodd
Felix Meiser
Adrian Russell
William H Bosch
Matt Callahan
Original Assignee
Iceutica Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009901741A external-priority patent/AU2009901741A0/en
Application filed by Iceutica Pty Ltd filed Critical Iceutica Pty Ltd
Publication of MX2011011217A publication Critical patent/MX2011011217A/es
Publication of MX360545B publication Critical patent/MX360545B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules
    • A01N25/14—Powders or granules wettable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

La presente invención se refiere a un método para mejorar el perfil de disolución de un material biológicamente activo que comprende las etapas de molienda en seco de un material biológicamente activo sólido y una matriz de molienda que se puede moler en un molino que comprende una pluralidad de cuerpos de molienda, por un periodo de tiempo suficiente para producir partículas del material biológicamente activo dispersado en al menos un material de molido parcialmente molido.
MX2011011217A 2009-04-24 2010-04-23 Método para mejorar el perfil de disolución de un material biológicamente activo. MX360545B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17230109P 2009-04-24 2009-04-24
AU2009901741A AU2009901741A0 (en) 2009-04-24 Method for Improving the Dissolution Profile of a Biologically Active Material
PCT/AU2010/000465 WO2010121321A1 (en) 2009-04-24 2010-04-23 Method for improving the dissolution profile of a biologically active material

Publications (2)

Publication Number Publication Date
MX2011011217A true MX2011011217A (es) 2012-02-08
MX360545B MX360545B (es) 2018-10-26

Family

ID=43010604

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011217A MX360545B (es) 2009-04-24 2010-04-23 Método para mejorar el perfil de disolución de un material biológicamente activo.

Country Status (21)

Country Link
US (5) US20120165323A1 (es)
EP (1) EP2421516A4 (es)
JP (3) JP5898613B2 (es)
KR (3) KR101679522B1 (es)
CN (3) CN104825396A (es)
AP (2) AP3629A (es)
AU (2) AU2010239160B2 (es)
BR (1) BRPI1014277A2 (es)
CA (1) CA2759104C (es)
CO (1) CO6470804A2 (es)
EA (1) EA201171280A1 (es)
IL (1) IL215871B (es)
MA (1) MA33293B1 (es)
MX (1) MX360545B (es)
MY (1) MY163538A (es)
NZ (1) NZ595972A (es)
PH (1) PH12015501781A1 (es)
SG (1) SG175308A1 (es)
UA (1) UA110772C2 (es)
WO (1) WO2010121321A1 (es)
ZA (1) ZA201108647B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
KR101679522B1 (ko) * 2009-04-24 2016-11-24 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법
BRPI1014275B8 (pt) 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
NZ595903A (en) * 2009-04-24 2014-03-28 Iceutica Pty Ltd A novel formulation of metaxalone
CN102438592B (zh) * 2009-04-24 2016-09-14 伊休蒂卡有限公司 甲氧萘普酸的剂型
EP2421509B1 (en) * 2009-04-24 2017-11-22 Iceutica Pty Ltd. Production of encapsulated nanoparticles at high volume fractions
BRPI1014276B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd produção de nanopartículas encapsuladas em escala comercial
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
US20150157646A1 (en) 2013-09-27 2015-06-11 Iceutica Inc. Abiraterone Steroid Formulation
CN104644556B (zh) * 2013-11-22 2018-05-22 沈阳药科大学 盐酸依福地平固体粉末及其制备方法
AU2015200340B2 (en) * 2014-02-05 2019-01-24 Upl Limited Combinations
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CA2951690A1 (en) 2014-06-09 2015-12-17 Biometry Inc. Low cost test strip and method to measure analyte
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
CA2988918A1 (en) * 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
JP6968062B6 (ja) * 2015-10-23 2021-12-15 ビーエーエスエフ ソシエタス・ヨーロピアBasf Se 発香性物質及び香味物質とビニルラクタムポリマーとの固溶体
CN105385739B (zh) * 2015-12-09 2017-09-29 梁尚文 －种从金边蚂蟥中制取蛋白肽的方法
CN109715067B (zh) 2016-07-19 2022-05-17 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
CN107853670A (zh) * 2017-10-30 2018-03-30 潍坊友容实业有限公司 一种盐地碱蓬生物盐提取方法
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
CN116327960A (zh) 2018-05-11 2023-06-27 南京清普生物科技有限公司 一种美洛昔康组合物、制剂及其制备方法与应用
AU2019332696A1 (en) * 2018-08-31 2021-03-18 Kemin Industries, Inc. Technology for water dispersible phospholipids and lysophospholipids
US20210338613A1 (en) * 2018-10-05 2021-11-04 Dyve Biosciences, Inc. Formulations and methods for transdermal administration of ketones
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
CN113133970A (zh) * 2020-01-17 2021-07-20 美国琛蓝营养制品股份有限公司 一种姜黄素复合物及其制备方法和检测方法
TR202017034A2 (tr) * 2020-10-26 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Kuru öğütme yöntemi̇ i̇le hazirlanan ve çözünme hizi arttirilmiş selekoksi̇b i̇çeren farmasöti̇k kompozi̇syonlar
CN114306253B (zh) * 2021-11-16 2023-08-22 扬子江药业集团广州海瑞药业有限公司 格列美脲片剂及其制备方法
CN113996161B (zh) * 2021-12-30 2022-04-19 河北鑫鹏新材料科技有限公司 一种硫转移剂及其制备方法和应用
CN114732009B (zh) * 2022-06-13 2022-08-23 山东百农思达生物科技有限公司 一种含有吡唑醚菌酯和烯酰吗啉的水分散粒剂的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
JP4117811B2 (ja) * 1997-04-22 2008-07-16 日本化薬株式会社 フルタミド製剤及びその製法
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ATE424811T1 (de) * 2000-08-31 2009-03-15 Jagotec Ag Gemahlene partikel
JP2004099442A (ja) * 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
US20090028948A1 (en) * 2004-12-31 2009-01-29 Iceutica Pty Ltd Nanoparticle composition and methods of synthesis thereof
WO2007070852A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for parenteral administration
EP1973523A2 (en) * 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US8808751B2 (en) * 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
JP5508003B2 (ja) * 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
BRPI1014275B8 (pt) * 2009-04-24 2021-05-25 Iceutica Pty Ltd composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos
CN102438610A (zh) * 2009-04-24 2012-05-02 伊休蒂卡有限公司 双氯芬酸的新剂型
KR101679522B1 (ko) * 2009-04-24 2016-11-24 아이슈티카 피티와이 리미티드 생물학적 활성 물질의 용해 프로파일 개선방법

Also Published As

Publication number Publication date
BRPI1014277A2 (pt) 2016-10-18
AP2011005994A0 (en) 2011-12-31
EA201171280A1 (ru) 2012-09-28
AU2015243003A1 (en) 2017-05-04
CN103830243A (zh) 2014-06-04
KR101679522B1 (ko) 2016-11-24
US20130277468A1 (en) 2013-10-24
MY163538A (en) 2017-09-15
US20210401753A1 (en) 2021-12-30
JP2012524717A (ja) 2012-10-18
SG175308A1 (en) 2011-11-28
US20200375903A1 (en) 2020-12-03
NZ595972A (en) 2014-01-31
KR101873500B1 (ko) 2018-08-02
AP3629A (en) 2016-03-08
IL215871A0 (en) 2012-01-31
CA2759104C (en) 2019-01-29
CN104825396A (zh) 2015-08-12
AU2010239160B2 (en) 2014-10-02
MX360545B (es) 2018-10-26
KR20150013948A (ko) 2015-02-05
JP6619386B2 (ja) 2019-12-11
KR20120047207A (ko) 2012-05-11
AP2015008965A0 (en) 2016-01-31
CO6470804A2 (es) 2012-06-29
CN102438600A (zh) 2012-05-02
WO2010121321A1 (en) 2010-10-28
CA2759104A1 (en) 2010-10-28
IL215871B (en) 2019-07-31
JP5898613B2 (ja) 2016-04-06
UA110772C2 (uk) 2016-02-25
EP2421516A4 (en) 2012-11-07
US20180169018A1 (en) 2018-06-21
EP2421516A1 (en) 2012-02-29
KR20160098535A (ko) 2016-08-18
AU2010239160A1 (en) 2011-11-10
MA33293B1 (fr) 2012-05-02
JP2015199736A (ja) 2015-11-12
JP2017222643A (ja) 2017-12-21
US20120165323A1 (en) 2012-06-28
ZA201108647B (en) 2013-01-30
PH12015501781A1 (en) 2016-10-03

Similar Documents

Publication Publication Date Title
PH12015501781A1 (en) Method for improving the dissolution profile of a biologically active material
NZ614995A (en) Methods for the preparation of biologically active compounds in nanoparticulate form
NZ629438A (en) Inhalable pharmaceutical compositions
NZ595902A (en) Method for the production of commercial nanoparticle and microparticle powders
EP2125230B8 (de) Verfahren zum kontinuierlichen trocken-mahl-betrieb einer turm-reib-mühle und turm-reib-mühle
WO2012027711A3 (en) Compositions and methods for treating bone defects
MY148467A (en) Milling apparatus
ZA200905828B (en) Bearing for a shaft of a gyratory crusher and method of adjusting the gap width of the crusher
MX354137B (es) Composiciones topicas de minociclina y metodos de uso de la misma.
EP2000553A4 (en) LAMINATE MATERIAL FOR BREAKING CRACK WITH EXCELLENT RIPTURE BREAKING CAPACITY, HOT FORK ROD ELEMENT HAVING EXCELLENT RIPTURE CRACKING CAPACITY AND RUPTURE CRACKING ROD
BRPI0815817A2 (pt) fresa laminadora para triturar um material sólido, como matérias primas de cimento e materiais similares.
BRPI0822278A2 (pt) Britador, instalação de britagem, método para ajustar o curso de um britador, e, produto de software de computador
WO2012014083A3 (en) Frataxin mutants
ATE551123T1 (de) Mühle und mahlverfahren
MY191875A (en) Solid dosage form
WO2009094612A3 (en) In-line milling system
BRPI1014057A2 (pt) método para controlar a alimentação de material a um moinho de rolos e tais moinhos similares.
WO2013159947A3 (de) Walzenmühle
PL2480376T3 (pl) Szlifierka wielotarczowa, w szczególności do obróbki kamienia i podobnych materiałów
PL3595816T3 (pl) Układ i sposób do regulacji głębokości złoża materiału w młynie pyłowym
WO2013124106A3 (de) Vertikalrollenmühle und verfahren zum betreiben einer vertikalrollenmühle
MX344445B (es) Molino de cilindros y procedimiento para la trituración de material a moler quebradizo.
EP3714981C0 (de) Aufbereitungsanlage, insbesondere brechanlage, insbesondere gesteinsbrecher
EG25603A (en) Roller mill for grinding particulate material
GB0810227D0 (en) Synergistic binder composition, method for making same and tablets of an active and said binder having advantages hardness and friability

Legal Events

Date Code Title Description
FG Grant or registration